Delivery Order SPE2DR25D1100-SPE2DR26FDB3Z
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,725.36 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (quantity: 30-unit bottles). This competitively awarded, firm fixed price contract is scheduled for completion by November 28, 2025, and represents a non-set-aside procurement. The award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion...
- The Defense Logistics Agency awarded a delivery order valued at $28.6K to Amerisourcebergen Drug Corp for the supply of Vemlidy 25mg tablets (30-count) with a firm fixed-price structure. The award, issued on January 14, 2026, is scheduled for completion by February 11, 2026, and will be performed at the contractor's location in Conshohocken, Pennsylvania. This competitive, non-set-aside contract represents a task order under Amerisourcebergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $46,670.65 to AmerisourceBergen Drug Corp on January 14, 2026, for the supply of Vemlidy 25 mg tablets in quantities of 30 units. This firm fixed-price, non-set-aside contract is scheduled for completion by January 15, 2026, with performance taking place at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,316.31 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on January 23, 2026, with an ultimate completion date of January 26, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a task order executed under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets in a quantity of 30 units, valued at $20,868.93. This is a firm fixed price delivery order with no set-aside designation, issued on November 17, 2025, with an ultimate completion date of November 18, 2025. The work will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,139.66 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on October 29, 2025, with an ultimate completion date of October 30, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $8,845.60 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on January 15, 2026, with an ultimate completion date of January 16, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a task order issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $3,871.73 delivery order to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of Vemlidy 25 mg tablets (30-count units). This firm fixed-price, non-set-aside contract is scheduled for completion by January 14, 2026, with performance at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $10,560.80 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $42,302.47 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on December 4, 2025, with an ultimate completion date of December 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FDB3ZDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,892.71 to AmerisourceBergen Drug Corp for the supply of Vemlidy 25 mg tablets (30-count units) on January 23, 2026, with completion scheduled for January 26, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a task order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion vehicle running through December 2026 that serves as the primary mechanism for delivering pharmaceutical products and medical supplies to military healthcare programs globally. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (operating as AmerisourceBergen), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across defense and civilian healthcare systems. The company's extensive portfolio includes brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. Vemlidy, an antiviral medication indicated for hepatitis B treatment, continues the contractor's demonstrated capability to efficiently fulfill government requirements for essential pharmaceutical commodities supporting military treatment facilities and veterans' healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 1/22/26 |